Prostate adenocarcinoma immunohistochemistry. Changes of protein expression in prostate cancer having lost its androgen sensitivity.


The current situation of cancer morbidity and mortality in the light of the National Cancer Registry.

Its relevance as a novel biomarker in many kinds of cancer has been recently published and data also suggest that IMP3 may play an important role in malignant transformation 3. Cytoplasmic expression of IMP3 has been associated with a more aggressive phenotype in many cancers including triple negative basal-like breast cancers, colon cancers, lung cancer and prostate cancer

Positron emission tomography in uro-oncology. Cancer Imaging ; 5: 1—7.

Agustín Zubillaga. La muestra estuvo conformada por 10 médicos y 8 enfermeras a quienes se les aplicó una encuesta a través de un cuestionario con escala tipo Likert el cual fue validado por la técnica de juicio de expertos. Los resultados indican que los encuestados manifiestan una tendencia positiva en cuanto a que a la consulta llegan pacientes cuyas madres usan las creencias y costumbres de sus ancestros para tratar las enfermedades que padecen, respetando y reconociendo el saber popular que poseen las madres de los pacientes.

Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med. Role of positron emission tomography in urological oncology. BJU Int. Ann Nucl Med. J Nucl Med. Prostate Cancer Prostatic Dis. Prostate-specific membrane antigen PSMA protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique.

prostate adenocarcinoma immunohistochemistry Trichomoniasis prosztatitis

Histopathology ; — Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of consecutive patients with intermediate to high risk prostate cancer.

J Urol. Novelties in diagnostics and treatment of prostate cancer. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics ; 5: — Clin Nucl Med. Eur Urol.

prostate adenocarcinoma immunohistochemistry Vitaminok a prosztatitis kezelésére a férfiakban

Sensitivity, specificity, and predictors of prostate adenocarcinoma immunohistochemistry 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis.

Eur Urol Focus Nov

prostate adenocarcinoma immunohistochemistry Prostatitis első jelei